Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) trial. While mRNA-1273 demonstrated high eff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2022-04, Vol.28 (4), p.823-830
Hauptverfasser:	Pajon, Rolando, Paila, Yamuna D., Girard, Bethany, Dixon, Groves, Kacena, Katherine, Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Mullane, Kathleen M., Frank, Ian, Denhan, Douglas, Kerwin, Edward, Zhao, Xiaoping, Ding, Baoyu, Deng, Weiping, Tomassini, Joanne E., Zhou, Honghong, Leav, Brett, Schödel, Florian
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 692/308/153 692/700/459/1748 Biomedical and Life Sciences Biomedicine Cancer Research Confidence intervals Copy number Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines Disease transmission Humans Immunization Infections Infectious Diseases Metabolic Diseases Molecular Medicine mRNA Neurosciences Placebos Respiratory diseases SARS-CoV-2 - genetics Severe acute respiratory syndrome coronavirus 2 United States Vaccination Vaccine efficacy Vaccines Viral diseases Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!